Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases

Fig. 4

The progression-free survival (PFS) of patients receiving immune checkpoint inhibitor (ICI) treatment in different groups. a The PFS of patients receiving ICI treatment in SWI/SNF-mutant-loss-of-function (SWI/SNF-mutant-LOF), SWI/SNF-mutant-non-LOF, and SWI/SNF-non-mutant groups. b The PFS of patients treated by ICIs carrying PBRM1 mutations was significantly longer than that of patients carrying the other SWI/SNF gene mutations. c The PFS of patients treated by ICIs carrying mutations in two or more SWI/SNF genes was not significantly different from that of patients with mutations in single gene. d The different ICI response of the SWI/SNF-mutant + low tumor mutational burden (TMB-L), the SWI/SNF-non-mutant + TMB-L cohort, and the SWI/SNF-mutant + high tumor mutational burden (TMB-H) cohorts

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us